Drugs / BMS-986141
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT03035734 | Jan → Feb 2017 | — | Bristol-Myers Squibb | Withdrawn | No outcome recorded |
| Phase 1 | NCT02985632 | Jan → May 2017 | — | Bristol-Myers Squibb | Withdrawn | No outcome recorded |
| Phase 1 | NCT02957448 | Nov 2016 → Jan 2017 | atherosclerotic cardiovascular disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02922452 | Sep → Nov 2016 | ischemic stroke | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02341638 | Sep 2014 → Sep 2015 | thrombotic disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05093790 | Mar → Nov 2022 | coronary artery disorder | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT02671461 | Apr 2016 → Mar 2017 | thrombotic disease | Bristol-Myers Squibb | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-986141 | “A Study to Evaluate the Effect of Rifampin on the Single-dose Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects” NCT02957448 ↗ |
| Known as | UDM-003183 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3716552 ↗ |
| Action | Inhibit | “BMS-986141 is a novel, oral, protease-activated, receptor 4 (PAR4)-antagonist” PMID 37394920 ↗ Dec 20231“Proteinase activated receptor 4 antagonist” CHEMBL3716552 ↗ |
| Modality | Small molecule | “BMS-986141 is a novel, potent, orally bioavailable, small-molecule antagonist specific for PAR4.” PMID 37394920 ↗ Dec 2023 |
| Route | Oral | “The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of a single and multiple oral doses of BMS-986141 in healthy subjects.” NCT02341638 ↗ |
| Target | F2RL3 | “Proteinase activated receptor 4 antagonist” CHEMBL3716552 ↗ |